FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
Oncogenesis, 2021 Cisplatin resistance is frequently occurred in ovarian cancer therapy, understanding its regulatory mechanisms is critical for developing novel treatment methods and drugs.
Shanyang He +7 more
doaj +1 more source
Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance
Cell Death and Disease, 2022 Hypoxia-induced cisplatin resistance is a major challenge during non-small cell lung cancer (NSCLC) treatment. Based on previous studies, we further explored the effect of eukaryotic initiation factor 5A2 (eIF5A2) in hypoxia-induced cisplatin resistance.
Guodong Xu +13 more
doaj +1 more source
Pulling a MAST1 on Cisplatin Resistance [PDF]
Cancer Cell, 2018 In this issue of Cancer Cell, Jin and colleagues use a kinome-wide screen to identify MAST1 as a cause of cisplatin resistance. They demonstrate that this kinase is a novel activator of MEK1 and the MAPK cascade and that it can harness pathway output to block cisplatin-induced cell death.
Ankita B, Jaykumar +2 more
openaire +2 more sources
Molecular mechanisms of cisplatin resistance [PDF]
Oncogene, 2011 Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.
L, Galluzzi +7 more
openaire +2 more sources
PeerJ, 2021 Backgrounds Cancer cell resistance to chemotherapy drugs such as Gemcitabine, Oxaliplatin, Cisplatin, Doxorubicin, and 5-fluorouracil account for the main reason of chemotherapy failure for HCC patients, especially for those with advanced HCC or metastasis patients.
Tang, Zuxiong +5 more
openaire +4 more sources
Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. [PDF]
PLoS ONE, 2014 Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a small fraction of them acquire resistance during therapy. Even when cisplatin treatment is successful the patient is often left with a residual teratoma at
Paolo B Abada, Stephen B Howell
doaj +1 more source
Targeting the PHB2-ACSL3 Lipid-Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer. [PDF]
Adv Sci (Weinh)ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Xu L +10 more
europepmc +2 more sources
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review [PDF]
, 2007 Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
Pavlakis, Nick +8 more
core +2 more sources
Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]
, 2009 Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
Pavlakis, Nick +5 more
core +2 more sources
Literature Review: Mekanisme Resistensi Kemoterapi Berbasis Platinum
Jurnal Kesehatan, 2020 Cisplatin is a type of platinum-based chemotherapy that is often used in the spectrum of solid neoplasms, including the ovaries, testicles, urinary vesicles, colorectal, lungs, and head-neck.
Amelia Rizky Khalidah
doaj +1 more source